Lilly's ED drug gets daily dose

Eli Lilly's tadalafil was the little blue pill's lesser sibling at first, but it's gained momentum, especially outside the U.S. With a low-dose pill approved yesterday by the FDA, is may just pull ahead domestically, too.

Taken daily, the low-dose version allows men to attempt sexual activity anytime. Previously, men had to take tadalafil ahead of time; it remained effective for 36 hours. Other treatments work for about four hours.

Lilly hopes that this new, more convenient dosing helps sales continue to grow: For the first nine months of 2007, the drug brought in $798 million, and the company expects it to top $1 billion for the full year. The nine-months results are 30 percent higher than same-period-last-year sales.

- here's Lilly's release
- read the article from the Indianapolis Star

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.